Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
Journal of Lipid Mediators|June 1, 1992
Pharmacological profile of TCV-309--a potent PAF antagonistZ Terashita, M Takatani, K NishikawaNihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|December 1, 1993
[Effect of CV-4151 on the cerebral hypoperfusion and production of thromboxane A2 following complete cerebral ischemia-reperfusion in dogs]G Kito, M Tanabe, Z TerashitaThrombosis Research|July 1, 1990
The role of thromboxane (TX) A2 in rabbit arterial thrombosis induced by endothelial damageY Imura, Z Terashita, K NishikawaBiochemical Pharmacology|May 1, 1985
Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the plateletZ Terashita, Y Imura, K NishikawaArchives of Gerontology and Geriatrics|May 1, 1989
Inhibition of platelet aggregation by idebenone and the mechanism of the inhibitionM Suno, Z Terashita, A NagaokaJournal of Lipid Mediators and Cell Signalling|January 1, 1996
Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic ringsZ Terashita, Y Imura, K NishikawaLife Sciences|July 14, 1986
Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988Y Imura, Z Terashita, K NishikawaBiochemical Pharmacology|December 15, 1990
Endothelin-1 and platelet activating factor stimulate thromboxane A2 biosynthesis in rat vascular smooth muscle cellsM Takayasu-Okishio, Z Terashita, K KondoThe Journal of Pharmacology and Experimental Therapeutics|October 1, 1987
A lethal role of platelet activating factor in anaphylactic shock in miceZ Terashita, Y Imura, A Shino, et al.Thrombosis Research|May 15, 1997
Effects of TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeysM Kawamura, N Tsuji, N Moriya, et al.Pageof 6